Ironwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Ironwood Pharmaceuticals (NASDAQ:IRWD) announced its quarterly earnings results on Thursday. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.04, FiscalAI reports. Ironwood Pharmaceuticals had a net margin of 37.38% and a negative return on equity of 81.40%. The company had revenue of $133.04 million during the quarter, compared to the consensus estimate of $119.99 million.

Here are the key takeaways from Ironwood Pharmaceuticals’ conference call:

• LINZESS had its strongest-ever quarterly net sales at $325 million, and Ironwood raised 2026 guidance to $1.2 billion–$1.25 billion, implying growth of more than 35%. Management cited improved net pricing and mid-single-digit prescription demand growth, while noting that pricing tailwinds may not persist beyond this year.
• Ironwood reported $98 million in record adjusted EBITDA and $60 million in GAAP net income for Q3. It paid down $60 million of debt during the quarter and expects year-end debt below $300 million, while funding apraglutide development.
• The company said STARS-2 site activation is on track, with more than 100 sites planned across 22 countries and activated sites recruiting patients. The estimated primary completion remains October 2028, supporting a potential 2029 NDA submission.
• CEO Tom McCourt plans to retire, with Chief Commercial Officer Tammy Gaskins set to become CEO on January 1, 2027. Management emphasized continuity, citing Gaskins’ role in LINZESS’s growth and the company’s turnaround.

Ironwood Pharmaceuticals Trading Up 8.9%

IRWD traded up $0.36 during trading on Friday, reaching $4.39. 3,963,094 shares of the company’s stock were exchanged, compared to its average volume of 1,782,490. Ironwood Pharmaceuticals has a one year low of $1.88 and a one year high of $5.78. The stock has a market capitalization of $725.40 million, a PE ratio of 4.88 and a beta of 0.25. The firm has a fifty day moving average price of $3.91 and a two-hundred day moving average price of $3.97.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on IRWD shares. Jefferies Financial Group raised Ironwood Pharmaceuticals to a “hold” rating in a report on Friday, September 25th. Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Weiss Ratings raised Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Finally, Wall Street Zen upgraded Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $6.23.

Key Stories Impacting Ironwood Pharmaceuticals

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Ironwood reported Q3 adjusted earnings of $0.36 per share, above analyst expectations, while net income rose 49% year over year. It raised 2026 revenue guidance to $485 million–$510 million, above the roughly $470.5 million consensus, and increased its EBITDA outlook. Management also cited stronger Linzess sales expectations and profitability. Ironwood Q3 net income rises and outlook increases
• Neutral Sentiment: Revenue commentary was inconsistent: one Zacks headline described revenue as missing expectations, while reported figures of $133.04 million exceeded the estimate of $119.99 million cited elsewhere. Zacks Q3 earnings and outlook coverage

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood’s principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.